Independent regulatory intelligence
Know the rules.
Understand the clinic.
Clear, sourced analysis of UK private clinic regulation, licensing and enforcement—for patients, practitioners and decision-makers.
The intelligence desk
Explore by section
From weekly regulatory movement to deeper enforcement and scientific analysis.
Regulatory Pulse
A weekly source-by-source scan of what changed in UK private clinic regulation — and what stayed the same.
1 article
Enforcement Watch
Rulings, investigations and enforcement patterns affecting UK private clinics, pharmacies and healthcare advertising.
4 articles
Scientific Digest
New clinical research and evidence interpreted through the lens of UK private clinic safety and regulation.
5 articles
Guides
Evergreen guides to UK clinic licensing, legislation, prescribing rules and regulatory responsibilities.
3 articles
Regulatory Updates
Material UK regulatory, policy and medicine-approval developments with direct relevance to private clinics.
3 articles
Recently published
Latest analysis
-
Scotland licensing framework launches July 22
Scotland's non-surgical procedures framework starts being built on 22 July 2026. What the commencement order activates — and what stays on hold until 2027.
-
GLP-1 eye risk: what the new review found
New observational evidence found no overall increase in ocular disorders, but uncertainty and the MHRA semaglutide warning still matter for clinics.
-
Private scripts surged 134% — CQC report
Weekly regulatory scan: CQC reports a 134% rise in private CBPM prescribing and records what changed across six UK regulatory sources.
-
Wegovy approved for liver disease: new clinic opportunity
The MHRA approved Wegovy to treat MASH liver disease. This update explains what it means for private clinics prescribing semaglutide.
-
PJ analysis: online pharmacy weight loss prescribing safety
Research on safety risks in online pharmacy weight-loss prescribing and how it connects to GPhC enforcement.
-
Major review confirms GLP-1 safety for weight loss
A Nature Medicine review of 56 trials covering semaglutide and tirzepatide, with implications for UK clinic prescribing.